LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Pfizer

Fechado

SetorSaúde

22.82 1.06

Visão Geral

Variação de preço das ações

24h

Atual

Mín

22.45

Máximo

22.82

Indicadores-chave

By Trading Economics

Rendimento

2.6B

3B

Vendas

-4B

14B

P/E

Médio do Setor

16.732

56.602

EPS

0.92

Rendimento de Dividendos

7.72

Margem de lucro

21.633

Funcionários

81,000

EBITDA

2B

4.5B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+26.88% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

7.72%

2.45%

Próximos Ganhos

29 de jul. de 2025

Próxima data de dividendos

13 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-14B

131B

Abertura anterior

21.76

Fecho anterior

22.82

Sentimento de Notícias

By Acuity

43%

57%

150 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Pfizer Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de mai. de 2025, 18:41 UTC

Grandes Movimentos do Mercado

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29 de abr. de 2025, 11:24 UTC

Ganhos

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

15 de mai. de 2025, 15:20 UTC

Principais Notícias

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12 de mai. de 2025, 22:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 de mai. de 2025, 18:45 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 de mai. de 2025, 17:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 de mai. de 2025, 09:02 UTC

Ações em Alta

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7 de mai. de 2025, 17:01 UTC

Principais Notícias

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 de mai. de 2025, 09:30 UTC

Principais Notícias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5 de mai. de 2025, 15:13 UTC

Conversa de Mercado
Ganhos

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1 de mai. de 2025, 14:07 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 de mai. de 2025, 11:58 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 de mai. de 2025, 11:06 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 de mai. de 2025, 10:48 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29 de abr. de 2025, 19:47 UTC

Ganhos

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 de abr. de 2025, 18:11 UTC

Ganhos

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29 de abr. de 2025, 15:22 UTC

Ganhos

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 de abr. de 2025, 12:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29 de abr. de 2025, 11:46 UTC

Ganhos

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 de abr. de 2025, 11:42 UTC

Ganhos

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 de abr. de 2025, 11:12 UTC

Ganhos

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29 de abr. de 2025, 10:52 UTC

Ganhos

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29 de abr. de 2025, 10:51 UTC

Ganhos

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29 de abr. de 2025, 10:50 UTC

Ganhos

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29 de abr. de 2025, 10:47 UTC

Ganhos

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29 de abr. de 2025, 10:47 UTC

Ganhos

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29 de abr. de 2025, 10:46 UTC

Ganhos

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29 de abr. de 2025, 10:45 UTC

Ganhos

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

29 de abr. de 2025, 10:45 UTC

Ganhos

Pfizer 1Q EPS 52c >PFE

29 de abr. de 2025, 10:45 UTC

Ganhos

Pfizer 1Q Adj EPS 92c >PFE

Comparação entre Pares

Variação de preço

Pfizer Previsão

Preço-alvo

By TipRanks

26.88% parte superior

Previsão para 12 meses

Média 27.94 USD  26.88%

Máximo 32 USD

Mínimo 24 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Pfizer - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

5

Comprar

13

Manter

0

Vender

Pontuação Técnica

By Trading Central

22.855 / 23.85Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

150 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.